№ files_lp_3_process_7_076494
File format: docx Character count: 61919 File size: 2014 KB
Year: 2023
Region / city: Australia
Subject: Pharmaceutical treatment for primary biliary cholangitis
Document type: Authority submission for PBS listing
Organization: Emerge Health Pty Ltd
Author: Emerge Health Pty Ltd
Target audience: Healthcare professionals, gastroenterologists, hepatologists, prescribers
Period of validity: Ongoing
Approval date: Not specified
Date of changes: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
7.07 NIVOLUMAB, Injection concentrate for I.V. infusion, 40 mg in 4 mL, 100 mg in 10 mL, Opdivo®, as monotherapy, or in combination with IPILIMUMAB, Injection concentrate for I.V. infusion, 50 mg in 10 mL, 200 mg in 40 mL, Yervoy®, Bristol-Myers Squibb
Year: 2023
Region / City: Australia
Subject: Cancer Treatment / Immunotherapy
Document Type: Submission
Organ / Institution: Pharmaceutical Benefits Advisory Committee (PBAC)
Author: Bristol-Myers Squibb
Target Audience: Medical professionals, healthcare policy makers, pharmaceutical industry stakeholders
Period of Validity: Ongoing
Approval Date: Not specified
Date of Changes: Not specified
Topics: Obeticholic ursodeoxycholic monotherapy